Topiramate
- Generic Name
- Topiramate
- Brand Names
- Eprontia, Qsymia, Qudexy, Topamax, Trokendi
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21NO8S
- CAS Number
- 97240-79-4
- Unique Ingredient Identifier
- 0H73WJJ391
- Background
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy in adults.
...
- Indication
Topiramate is indicated for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for both adult and pediatric patients above 2 years old 3)Adjunctive therapy for seizures associat...
- Associated Conditions
- Alcohol Dependency, Epilepsy, Primary Generalized Tonic-Clonic Seizures, Generalized Tonic-Clonic Seizures, Lennox-Gastaut Syndrome, Migraine, Moods Disorders, Partial-Onset Seizures, Seizures, Weight
- Associated Therapies
- Chronic Weight Management therapy, Weight Reduction
Beneficial Side Effects of Topiramate in Obese Patients Undergoing Total Joint Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Stanford University
- Registration Number
- NCT04613024
- Locations
- 🇺🇲
Stanford University, Palo Alto, United States Minor Outlying Islands
Medications After Adolescent Bariatric Surgery
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Janey Pratt
- Registration Number
- NCT04572217
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 80
- Registration Number
- NCT04453306
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04401137
- Locations
- 🇰🇷
Seoul National University Hospital, Dept. of Clinical Pharmacology, Seoul, Korea, Republic of
Study on the Optimal Strategy of Chinese Patients With Bulimia Nervosa After Fluoxetine Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 550
- Registration Number
- NCT04154813
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 777
- Registration Number
- NCT03828539
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Ataturk University
- Target Recruit Count
- 90
- Registration Number
- NCT03767062
- Locations
- 🇹🇷
Mustafa Ceylan, Erzurum, Turkey
Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine
- Conditions
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Ataturk University
- Target Recruit Count
- 120
- Registration Number
- NCT03712917
- Locations
- 🇹🇷
Ataturk University Resarch Hospital, Erzurum, Turkey
Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD
- Conditions
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 150
- Registration Number
- NCT03667846
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Conditions
- Interventions
- Drug: Tranexamic acid (TXA)Drug: HydrocodoneDrug: labetalolDrug: metforminDrug: nifedipineDrug: oxycodoneDrug: clindamycinDrug: azithromycinDrug: escitalopramDrug: sertralineDrug: CiprofloxacinDrug: ondansetronDrug: DoxycyclineDrug: LevofloxacinDrug: MethylphenidateDrug: CitalopramDrug: SumatriptanDrug: CyclobenzaprineDrug: FurosemideDrug: RosuvastatinDrug: GabapentinDrug: HydrochlorothiazideDrug: HydroxyureaDrug: TrazodoneDrug: TopiramateDrug: ValganciclovirDrug: RemdesivirDrug: VenlafaxineDrug: VerapamilDrug: FluvoxamineDrug: AnakinraDrug: TocilizumabDrug: AmoxicillinDrug: BupropionDrug: BuprenorphineDrug: LevetiracetamDrug: ParoxetineDrug: Duloxetine
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Loma Linda University Health, Loma Linda, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.